FCGR2A and neoplasm: Although this approach would likely dampen the efficacy of tumour-targeting mAbs which require activatory FcγR binding as opposed to CD32B for function, mutating these residues has been shown to augment the efficacy of mAbs targeting TNFR superfamily members which benefit from CD32B engagement (see above).